Every 8-K that Stryker Corporation (SYK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SYK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SYK filings page.
Stryker Corporation announced a planned CEO transition: Kevin A. Lobo will resign as Chief Executive Officer on December 31, 2026, and become Executive Chair on January 1, 2027. Spencer S. Stiles, currently President and Chief Operating Officer, will become CEO and join the Board effective January 1; the Board’s size will increase from 10 to 11. Stiles has not been appointed to a Board committee at this time.
Lobo’s annual base salary, annual bonus target and employee benefit plan eligibility will remain unchanged after the transition, but he will not be eligible for new stock awards as Executive Chair. Effective January 1, 2027, Stiles’s annual base salary will increase to $1,320,000 and his annual bonus target to 150% of annual base salary; his benefit-plan eligibility remains unchanged. A recommendation will be made to independent directors in February 2027 to approve a Stiles award with aggregate target grant date fair value of $14,200,000, comprising 40% stock options and 60% performance stock units. Stryker also said annual net sales tripled, from $8.7 billion in 2012 to more than $26 billion in 2026.
Stryker Corporation reported strong second quarter 2026 results, with net sales of $6.6 billion, up 9.4%, and organic net sales growth of 9.0%. MedSurg and Neurotechnology sales rose 9.7% to $3.625 billion, while Orthopaedics grew 9.1% to $2.964 billion, driven mainly by higher unit volumes.
Reported gross margin was 68.3% and operating margin 25.2%, while adjusted operating income margin increased 170 basis points to 27.4%. Net earnings were $1.276 billion and reported diluted EPS increased 44.1% to $3.30. Adjusted net earnings were $1.424 billion and adjusted diluted EPS rose 17.9% to $3.69. Management stated it "made significant progress in our recovery from the cyber incident" and narrowed full‑year 2026 guidance to organic net sales growth of 8.3%–9.3% and adjusted diluted EPS of $14.95–$15.10, assuming a modestly positive pricing impact and slightly favorable foreign exchange.
Stryker Corporation has recast its prior-period financial statements to align with a new segment structure while highlighting a strong 2025 performance. Net sales grew 11.2% to $25,116 million, with MedSurg and Neurotechnology up 16.5% and Orthopaedics up 5.4%.
Reported net earnings were $3,246 million, or $8.40 diluted EPS, while adjusted net earnings reached $5,267 million and adjusted diluted EPS rose 11.8% to $13.63. The company invested $4,960 million in acquisitions, including the Inari Medical deal, and generated $5,044 million in operating cash flow, supporting dividends and debt repayment.
Stryker Corporation reported that William E. Berry, Jr., its Vice President and Chief Accounting Officer, will retire from that role effective September 1, 2026. Emily Baculik, currently Vice President, Corporate Controller, will become chief accounting officer on the same date.
Berry will serve as Advisor to the Chief Financial Officer from September 1, 2026 through August 15, 2027, receiving his current annual base salary of $510,000 and remaining eligible for a 2026 incentive bonus targeted at 50% of salary. Baculik’s annual base salary will increase to $420,000, with a bonus target of 45% of salary and a proposed February 2027 long‑term incentive grant valued at about $400,000 split between stock options and restricted stock units.
Stryker Corporation held its Annual Meeting of Shareholders on May 6, 2026, where shareholders voted on three proposals, including the election of directors. Director nominees generally received strong support, such as Sherilyn S. McCoy with 286,213,500 shares for and 3,785,435 against, and Rajeev Suri with 286,085,744 for and 3,887,285 against, alongside 30,151,420 broker non-votes for each nominee.
Stryker Corporation reported solid first quarter 2026 results with some margin pressure and lower adjusted earnings. Net sales rose 2.6% to $6.0 billion, driven by 5.0% growth in MedSurg and Neurotechnology to $3.2 billion, while Orthopaedics was roughly flat at $2.8 billion.
Reported operating income margin improved to 15.5% and reported diluted EPS increased 14.2% to $1.93. However, adjusted operating income margin narrowed to 21.1%, and adjusted diluted EPS declined 8.5% to $2.60 as non-GAAP adjustments fell versus last year.
The company reorganized its Orthopaedics portfolio into a new Ortho Tech business, combining Mako and related technologies with orthopaedic instruments, which recasts prior segment data without changing consolidated results. Stryker maintained its full year 2026 outlook for 8.0%–9.5% organic net sales growth and adjusted EPS of $14.90–$15.10, citing recovery from a recent cyber incident and continued business momentum.
Stryker Corporation filed an Amendment No. 1 to a prior current report to update investors on a March 11, 2026 cybersecurity incident. After further assessment, the company determined the attack had a material impact on its operations and on financial results for the first quarter of 2026.
Stryker reports that its global manufacturing, commercial, ordering and distribution systems are now fully operational, although the investigation remains ongoing. The company currently believes the incident has not had, and is not reasonably likely to have, a material impact on its 2026 full-year guidance, and plans to discuss first-quarter results and its guidance in more detail when it reports earnings on April 30, 2026.
Stryker Corporation provides an update on a previously disclosed cybersecurity incident that disrupted its corporate network, including parts of its Microsoft environment. Working with Palo Alto Networks’ Unit 42, third-party experts, and law enforcement, Stryker reports the incident is believed to be contained.
Current forensic analysis has not identified malicious activity directed toward customers, suppliers, vendors, or partners, nor evidence that the threat actor accessed their systems as a result of this incident. Stryker is prioritizing restoration of systems that support ordering, shipping, and manufacturing, which it says are ramping back up, while it continues to assess whether the incident is reasonably likely to have a material operational or financial impact.
Stryker Corporation reports an ongoing cybersecurity incident that disrupted its global Microsoft environment and is affecting order processing, manufacturing and shipping. The company currently believes its patient-related services have not been disrupted and its connected products were not impacted.
An internal investigation continues, and the full scope, nature and operational or financial impacts are not yet known. Stryker also highlights potential risks including data integrity issues, regulatory scrutiny, litigation, reputational damage and adverse effects on revenue, operating income, cash flows and liquidity.
Stryker Corporation reported a cybersecurity incident that disrupted its global Microsoft-based information technology environment. After detecting the issue on March 11, 2026, the company activated its cybersecurity response plan, brought in external advisors and experts, and believes the incident is currently contained with no indication of ransomware or malware.
The disruption is limiting access to certain information systems and business applications that support Stryker’s operations and corporate functions, and a full restoration timeline is still unknown. Stryker is using business continuity measures to keep serving customers, while an ongoing investigation evaluates the scope, operational effects, and any financial impact. The company has not yet determined whether the incident is reasonably likely to have a material impact.
Stryker Corporation filed a current report to note that it issued a press release on January 29, 2026 announcing its fourth quarter and full-year 2025 operating results and 2026 outlook. The press release is furnished as Exhibit 99.1 and is not treated as filed for liability purposes under the Exchange Act.
Stryker Corporation announced a leadership transition effective January 1, 2026. Spencer Stiles, currently Group President, Orthopaedics, will become President and Chief Operating Officer. Dylan Crotty, currently President, Instruments, will be promoted to Group President, Orthopaedics.
Both executives have 27-year careers at Stryker with leadership roles across Orthopaedics, MedSurg and Neurotechnology, Trauma & Extremities and international regions. Under a letter agreement, Mr. Stiles’s annual base salary will increase to $1,000,000 with a bonus target equal to 100% of salary and a recommended long-term incentive grant with a target value of about $6,000,000, split between stock options and performance stock units, subject to committee approval. Mr. Crotty’s base salary will rise to $700,000 with an 85% bonus target and a recommended long-term incentive grant of about $3,000,000 on similar terms.
Stryker Corporation filed a current report to furnish a press release announcing its third quarter 2025 operating results. The company states that the press release, dated October 30, 2025, is attached as Exhibit 99.1.
The report clarifies that the information in the press release and this filing is being furnished rather than filed, which affects how it is treated under securities laws and future SEC filings. The document is signed on behalf of Stryker by its Vice President and Chief Financial Officer.